Patient-reported Outcomes in Subjects with Neuropathic Pain Receiving Pregabalin: Evidence from Medical Practice in Primary Care Settings

Navarro, Ana; Saldaña, María T.; Pérez, Concepción; Torrades, Sandra; Rejas, Javier

doi:10.1111/j.1526-4637.2010.00824.x

Cited by 37 publications

(31 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fact that so few patients discontinued the study due to lack of efficacy ( 3.4% across the groups) also indicates the pain relief was meaningful. The robustness of the pain relief in these patient subgroups was of similar magnitude to improvements observed in other smaller observational, 8-12-week studies of pregabalin in usual clinical settings in patients with neuropathic pain arising from a variety of underlying causes [39][40][41] and greater than in other observational studies in Well-being for each of the questions was rated as 1=always, 2=most of the time, 3=fairly often, 4=sometimes, 5=rarely, 6=never.…”

Section: Fig (6) Mean General Well-being Impairment Scorementioning

confidence: 75%

Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study

Toelle¹

2012

TOPAINJ

View full text Add to dashboard Cite

Abstract:Background: Neuropathic pain is associated with many conditions. Pregabalin has demonstrated efficacy in randomized, controlled trials (RCTs) in peripheral and central neuropathic pain. Observational studies complement findings from RCTs by enabling an agent to be studied in real-world patients and circumstances. Methods:Patients with neuropathic pain were treated with pregabalin 150-600 mg/day in this 6 week observational study. Analyses of subsets of patients with painful diabetic peripheral neuropathy (DPN; n=4633), back pain with a neuropathic component (n=3800), and cancer-related neuropathic pain (n=345) were undertaken. Results:The mean pregabalin doses ranged from 219 to 250 mg/day across the disease groups. Mean baseline pain scores (6.4 to 7.0 across the three disease states) indicated patients had moderate to severe pain. Pregabalin was associated with a rapid and significant reduction in pain from week 1 to endpoint in all groups. Over 80% in each of the groups had a 30% pain reduction in their pain at 6 weeks, and over two-thirds had a 50% reduction. Pain-related sleep interference decreased rapidly and significantly. Most patients (87%) were either very satisfied or satisfied with the action of pregabalin. General well-being improved significantly over the 6 weeks. Pregabalin was generally well tolerated; the most common adverse event overall was dizziness (1.4%). Few patients ( 6.1%/group) discontinued due to adverse events. Conclusions:In neuropathic pain patients in day-to-day practice, pregabalin was associated with notable reductions in pain and sleep interference. The benefits of pregabalin were reflected in the high level of patient satisfaction and improvement in general well-being.

show abstract

Section: Fig (6) Mean General Well-being Impairment Scorementioning

confidence: 75%

Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study

Toelle¹

2012

TOPAINJ

View full text Add to dashboard Cite

show abstract

“…90 experience with pregabalin in the clinical practice setting Besides to the previously commented naturalistic studies in patients with refractory pain, we have run a series of studies and analyses of pregabalin for the treatment of various neuropathic conditions in the clinical practice setting. [91][92][93][94][95][96] Two of these studies were run with a similar design: 12-week studies in patients with chronic pain treated in the primary care setting with a diagnosis of neuropathic pain 91,92 or painful radiculopathy. 93,94 In addition, we performed a specific analysis of patients with trigeminal neuralgia.…”

Section: Pregabalin In Combination Therapymentioning

confidence: 99%

A Review of Pregabalin for the Treatment of Peripheral and Central Neuropathic Pain and Its Place in the Treatment of Chronic Pain

Pérez¹,

Margarit²,

Gálvez³

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Pregabalin is an α2-δ ligand indicated for the treatment of peripheral and central neuropathic pain. In this article, we will review the pharmacodynamics, pharmacokinetics, randomized clinical trials supporting its efficacy for a wide array of neuropathic painful conditions, and the tolerability of this medication. We will comment the main differences with gabapentin, its parent compound, both from the pharmacological and clinical perspective. Our experience in the clinical practice setting with pregabalin, its use in patients with refractory neuropathic pain and its rational use in combination regimens will also be reviewed. With all this information in mind, the place of pregabalin in the pharmacotherapy of neuropathic pain is explored, mainly through the review of recent clinical guidelines which, in fact, place pregabalin among the first-line treatments for the management of most neuropathic painful conditions.

show abstract

“…192 Patients with chronic pain of peripheral neuropathic origin receiving pregabalin, both in monotherapy and as add-on therapy, showed substantial improvements in severity of pain and in the spectrum of associated symptoms, such as sleep disturbances, mood disorders, disability, and health-related quality of life. 193 In a recent prospective, open-label study, the administration of pregabalin in cancer patients with a NP component was studied. 194 One hundred-two cancer patients with definite NCP resistant to a combination of paracetamol, codeine, NSAIDs and methylprednisolone were randomly divided into two groups (pregabalin vs. opioids).…”

Section: 155mentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

Patient-reported Outcomes in Subjects with Neuropathic Pain Receiving Pregabalin: Evidence from Medical Practice in Primary Care Settings

Cited by 37 publications

References 57 publications

Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study

Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study

A Review of Pregabalin for the Treatment of Peripheral and Central Neuropathic Pain and Its Place in the Treatment of Chronic Pain

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Contact Info

Product

Resources

About